Cite

HARVARD Citation

    Wang, M. et al. (2019). Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin‐induced apoptosis. Thoracic cancer. 10 (4), pp. 918-929. [Online]. 
  
Back to record